Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of E8001 in Healthy Male Subjects
NCT04609852Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of E8001 in organ transplant rejection (4 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at Day 180, Maximum Observed Plasma Concentration for E8001 and 5 more. Started Oct 2020; status: completed.
02
Drugs
E8001
03
Conditions
organ transplant rejection
Beyond the preview
Go deeper on NCT04609852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609852.